Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.37, $0.42 better than the analyst estimate of $1.95. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $62.93 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.